DCE MRI in Patients With Pancreatic Cancer
Key facts
- Who runs it
- OHSU Knight Cancer Institute
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 77 people enrolled
- Started
- 31 Jan 2014
- Ended
- 7 Aug 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Ferumoxytol
- Record updated
- 31 July 2025
- Why it stopped
- Loss of funding
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- ALL PARTICIPANTS: A negative serum or urine pregnancy test for woman of childbearing potential
- ALL PARTICIPANTS: Ability to understand and the willingness to sign a written informed consent document
- GROUPS 1, 2, AND 3: "All participants" described above
- GROUPS 1, 2, AND 3: Must be consented for the Oregon Pancreatic Tumor Registry (OPTR)
- GROUPS 1, 2, AND 3: Group 1: participants identified as being high-risk for familial or hereditary pancreatic cancer, and must conform to one or more of the following requirements:; Have a strong family history of pancreatic cancer; this is defined as pancreatic cancer occurring in one first- degree relative and two other relatives, or two first- degree relatives; or,; Have a known high-risk genetic syndrome (e.g., BRCA 1\&2, STK11, CDNK2A, PRSS1, and MSH 2\&6)
- GROUPS 1, 2, AND 3: Group 2 participants identified as having IPMN on standard radiographic imaging that meets criteria for resection based on symptoms or on conventional imaging (computed tomography [CT] or MRI) findings
- GROUPS 1, 2, AND 3: Group 3 participants must have pathologically- confirmed pancreatic adenocarcinoma, with or without the need for neoadjuvant chemotherapy prior to surgical resection
- HEALTHY VOLUNTEERS (Group 4): Must meet inclusion criteria for "all participants" described above
- HEALTHY VOLUNTEERS (Group 4): Group 4 participants must have no history of cancer, pancreatic disease, or family history of pancreatic cancer; Family history will be defined as pancreatic cancer occurring in one first-degree relative and two other relatives, or two first-degree relatives
Who cannot take part
- Participants with concurrent clinical diagnosis, evidence of suspected hemochromatosis, or other diseases of iron metabolism (i.e., iron overload)
- Participants who have a contraindication for MRI (e.g. metal in their bodies, a cardiac pacemaker, or other incompatible device), or are severely agitated or claustrophobic. (For patients that are eligible but there is a concern of metal in their bodies, the will be given the option if interested to have a x-ray completed prior to study enrollment to determine if they can proceed with the study MRI. Patients with a concern of metal in their bodies that don't agree to a x-ray will not be enrolled into the study.)
- Participants with multiple drug allergies, and/or subjects who have had an allergic reaction to any intravenous iron replacement product, or a known history of hypersensitivity to ferumoxytol
- Cirrhosis, cardiomyopathy, restrictive heart disease, or bronzing of the skin
- Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
- Participants with diagnosis of renal insufficiency or glomerular filtration rate (GFR) < 60 ml/min/1.73m\^2
- Participants unable or unwilling to give written, informed consent or to undergo MRI imaging
- Pregnant women are excluded from this study because there is an unknown, but potential risk, for adverse events, as small animal trials have linked ferumoxytol administration (at very high doses) to birth defects (e.g., soft-tissue malformations and decreased fetal weights); it is not known whether ferumoxytol is present in human milk; breastfeeding, however, should be discontinued if the mother receives ferumoxytol while nursing
- Adult patients who require monitored anesthesia for MRI scanning
- Participants with any contraindications to gadolinium-based contrast agents
Where in United States
- OHSU Knight Cancer InstitutePortland, United States
About the trial
What the trial wants to find out
This clinical trial studies an imaging technique known as dynamic contrast enhanced magnetic resonance imaging (DCE MRI) in identifying the presence of pancreatic cancer. DCE MRI is a procedure that takes detailed pictures of functional and structural properties inside the body using magnetic field imaging. These images may better characterize pancreatic cancer in patients at high risk or in patients who may have undergone chemotherapy for pancreatic cancer.
The 4 groups in the trial
- Arm I (High-risk for familial/hereditary pancreatic cancer)Treatment being tested
Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
Treatment: Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Ferumoxytol
- Arm II (IPMN)Treatment being tested
Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
Treatment: Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Ferumoxytol
- Arm III (Pancreatic cancer)Treatment being tested
Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection. Patients currently undergoing neoadjuvant therapy or who have already completed neoadjuvant therapy that were unable to undergo imaging at baseline and are now proceeding to resection will have one DCE MRI scan prior to surgical resection.
Treatment: Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Ferumoxytol
- Arm IV (Healthy volunteers)Existing treatment, for comparison
Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
Treatment: Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Ferumoxytol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
- Record updated
- 31 July 2025